Evidera collaborated with Takeda and The Leukemia & Lymphoma Society on a study looking at patient preferences for attributes of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) treatments, which was presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics and selected as a case study of good practice in engaging patients in preference research in the Patient Focused Medicines Development (PFMD) Book of Good Practices (Case 8) 2020.
A patient-centered benefit-risk assessment was also conducted using the preferences elicited in the Discrete Choice Experiment from the patient preference study. These separate findings were presented at the ASH 2020 meeting in a poster entitled, “Treatment of Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Using Tyrosine Kinase Inhibitors in Combination with Chemotherapy: A Patient-Centered Benefit-Risk Assessment”.
